Finance

Lists
CDXS:NASDAQ
Codexis Inc
$1.60
+6.67%
(+0.10) 1D
$1.59
-0.62% (-0.0100)
After hours
Closed: Aug 19, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CDXS...
Open
$1.51
High
$1.65
Low
$1.51
Mkt. cap
175.21M
Avg. vol.
1.34M
Volume
0.00
52-wk high
$3.06
52-wk low
$0.96
EPS
-$0.34
Beta
2.54
Shares outstanding
109.51M
No. of employees
146
Open
$1.51
High
$1.65
Low
$1.51
Mkt. cap
175.21M
Avg. vol.
1.34M
Volume
0.00
52-wk high
$3.06
52-wk low
$0.96
EPS
-$0.34
Beta
2.54
Shares outstanding
109.51M
No. of employees
146
News stories
From web sources and news partners
Profile
Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications. Wikipedia
About Codexis Inc
CEOJohn Nicols
Employees146
Founded2002
HeadquartersRedwood City, California, United States
SectorHealth care
Websitecodexis.com
Analyst ratings
Based on 4 analysts giving stock ratings to CDXS in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CDXS in the last 3 months.
Highest
Current $1.60
$11.00 (+587.50%)
Average
$7.00 (+337.50%)
Lowest
$2.00 (+25.00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Allison Bratzel
Piper Sandler
Buy
Maintained
$8.00
+400%
08/17/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$11.00
+587.5%
08/11/2026
Brendan Smith
TD Cowen
Hold
Maintained
$2.00
+25%
08/11/2026
Matt Hewitt
Craig-Hallum
Buy
Maintained
-
-
07/24/2026
Unknown Analyst
Jefferies
Buy
Reiterated
$3.50
+118.7%
04/01/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.13 / -$0.12
-8.33%miss
Revenue / Est. (USD)
14.92M / 13.82M
+7.89%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
8.60M
38.92M
15.25M
14.92M
Cost of goods sold
16.33M
13.76M
13.51M
15.22M
Cost of revenue
16.33M
13.76M
13.51M
15.22M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.22M
11.18M
9.78M
10.93M
Operating expense
11.22M
11.18M
9.78M
10.93M
Total operating expenses
27.55M
24.95M
23.29M
26.14M
Operating income
-18.95M
13.97M
-8.04M
-11.23M
Other non operating income
-
-
-
-
EBT including unusual items
-19.61M
9.62M
-8.67M
-12.00M
EBT excluding unusual items
-19.61M
13.33M
-8.67M
-12.00M
Income tax expense
8.00K
18.00K
36.00K
10.00K
Effective tax rate
-0.04%
0.19%
-0.42%
-0.08%
Other operating expenses
-
-
-
-
Net income
-19.62M
9.60M
-8.70M
-12.00M
Net profit margin
-228.05%
24.67%
-57.08%
-80.49%
Earnings per share
-0.22
0.14
-0.10
-0.13
Interest and investment income
634.00K
656.00K
665.00K
535.00K
Interest expense
-1.29M
-1.30M
-1.29M
-1.30M
Net interest expenses
-658.00K
-640.00K
-625.00K
-766.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-17.59M
15.32M
-6.76M
-10.02M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps